All In Biotech

NDA 213182 · Novo Nordisk INC

Rybelsus

Semaglutide · Oral

Last checked: Nov 20, 2026Latest source record: Jan 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 16, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

626

187 Phase 3, 161 recruiting

FAERS reports

7,735

4,368 serious, 180 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 16, 2020 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LabelMedication GuideLetter
2 products under this application
  • RYBELSUS · SEMAGLUTIDE 3MG · TABLET, ORAL · Prescription
  • RYBELSUS · SEMAGLUTIDE 7MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.

All 626 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,110
  • vomiting769
  • diarrhoea614
  • off label use484
  • decreased appetite465
  • constipation443
  • blood glucose increased372
  • weight decreased365
  • impaired gastric emptying345
  • headache325
  • fatigue313
  • dizziness305

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
20171
20182
20197
2020487
2021841
20221,038
20231,065
20241,519
20251,570
20261,203

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rybelsus (Semaglutide)

2024 spending

$1.89B

Beneficiaries

309,993

1,251,733 claims

Per beneficiary

$6,097

$30.59 per unit

View as table
YearSpending
2020$73,444,409
2021$454,563,823
2022$974,894,470
2023$1,665,906,943
2024$1,890,082,026

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 782 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.